Latest / GNN Daily Breaking News / Obesity Battle Heats Up Again as Novo Claws Way Back Into Race With Lilly

Transcript

Obesity Battle Heats Up Again as Novo Claws Way Back Into Race With Lilly · GNN Daily Breaking News

• 0:00
  Speaker 1: The global fight against obesity has reignited in the pharmaceutical
• 0:04
  Speaker 1: industry as Novo Nordisk pushes back into contention against rival
• 0:08
  Speaker 1: Eli Lilly. For years, Lili's breakthrough treatments positioned it as
• 0:13
  Speaker 1: the dominant player in the weight loss drug market, but
• 0:16
  Speaker 1: Novo is clawing its way back with new formulations, expanded production,
• 0:21
  Speaker 1: and aggressive clinical trial data. At the heart of this
• 0:24
  Speaker 1: battle are GLP one drugs, a class of treatments originally
• 0:28
  Speaker 1: developed for diabetes but now widely prescribed for weight management.
• 0:34
  Speaker 1: Lili's Minjaro and zep found have captured headlines and market share,
• 0:38
  Speaker 1: driving billions in revenue and reshaping the conversation around obesity care. Novo, however,
• 0:45
  Speaker 1: is determined not to be sidelined. Its flagship Weggavy and
• 0:49
  Speaker 1: Ozenpic remain powerful brands, and the company is investing heavily
• 0:53
  Speaker 1: in next generation therapies that promise longer lasting effects and
• 0:58
  Speaker 1: fewer side effects. Street analysts say the competition is intensifying
• 1:03
  Speaker 1: because demand is exploding. Obesity rates continue to rise globally,
• 1:08
  Speaker 1: and patients are increasingly seeking pharmaceutical solutions after decades of
• 1:12
  Speaker 1: limited options. Both companies are racing to expand manufacturing capacity
• 1:18
  Speaker 1: as shortages have frustrated patients and providers. Novo recently announced
• 1:23
  Speaker 1: new production facilities, while Lily is scaling up supply chains
• 1:27
  Speaker 1: to meet surging demand. The rivalry also extends to pricing
• 1:32
  Speaker 1: and insurance coverage. Lily has leveraged its momentum to secure
• 1:36
  Speaker 1: broader reimbursement deals, but Novo is countering with competitive pricing
• 1:41
  Speaker 1: strategies and lobbying efforts to ensure its drugs remain accessible.
• 1:45
  Speaker 1: The outcome of these battles will determine not only market share,
• 1:49
  Speaker 1: but also how quickly obesity treatments become mainstream. Beyond economics,
• 1:54
  Speaker 1: the stakes are deeply personal. For millions struggling with obesity.
• 1:59
  Speaker 1: These rugs represent hope for improved health outcomes, reduced risk
• 2:04
  Speaker 1: of chronic disease, and enhanced quality of life. The competition
• 2:09
  Speaker 1: between Novo and Lily is not just about profits, It
• 2:12
  Speaker 1: is about shaping the future of obesity care worldwide. Ultimately,
• 2:17
  Speaker 1: the renewed clash underscores the high stakes race in pharmaceutical innovation.
• 2:22
  Speaker 1: As Novo claws back into the fight and Lily defends
• 2:25
  Speaker 1: its lead, patients stand to benefit from faster innovation, wider access,
• 2:31
  Speaker 1: and a new era in the treatment of obesity,